Patents by Inventor Eiichi Kodama
Eiichi Kodama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295202Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R1 represents a halogen atom, an amino group which may be substituted, a C1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R2 represents a hydrogen atom or an amino protecting group; R3 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R4 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.Type: ApplicationFiled: April 5, 2023Publication date: September 21, 2023Applicant: FUJIFILM CorporationInventors: Hidenobu KUNIYOSHI, Takehiro Yamane, Takayuki Yamakawa, Shintaro Tanabe, Hideyasu Fujiwara, Eiichi Kodama
-
Publication number: 20210155644Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent.Type: ApplicationFiled: January 26, 2021Publication date: May 27, 2021Applicant: Fujifilm CorporationInventors: Hidenobu Kuniyoshi, Takehiro Yamane, Takayuki Yamakawa, Hideyasu Fujiwara, Eiichi Kodama
-
Publication number: 20210147456Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R1 represents a halogen atom, an amino group which may be substituted, a C1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R2 represents a hydrogen atom or an amino protecting group; R3 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R4 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.Type: ApplicationFiled: January 26, 2021Publication date: May 20, 2021Applicant: FUJIFILM CorporationInventors: Hidenobu KUNIYOSHI, Takehiro Yamane, Takayuki Yamakawa, Shintaro Tanabe, Hideyasu Fujiwara, Eiichi Kodama
-
Publication number: 20120225837Abstract: 1-(2-Fluoro-4-thio-?-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity.Type: ApplicationFiled: April 16, 2012Publication date: September 6, 2012Applicants: Kyoto University, Yamasa CorporationInventors: Eiichi KODAMA, Masao Matsuoka, Noriyuki Ashida
-
Patent number: 8039614Abstract: The present invention provides a method for producing a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen or a phosphoryl group. The present invention also provides the derivative, and a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. The derivative is useful as a medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: May 20, 2009Date of Patent: October 18, 2011Assignee: Yamasa CorporationInventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Publication number: 20110014649Abstract: The present invention relates to the production of an N36-binding peptide at low cost and in a large quantity utilizing a microorganism. More specifically, the present invention relates to a method for producing an N36-binding peptide comprising introducing a recombinant vector into which a DNA molecule encoding an N36-binding peptide that binds to an N36 protein derived from a retrovirus that causes immunodeficiency in a mammal has been incorporated into E. coli as a host to produce a transformant.Type: ApplicationFiled: July 26, 2007Publication date: January 20, 2011Applicant: GEKKEIKAN SAKE CO., LTD.Inventors: Hiroko Tsutsumi, Hiroki Ishida, Hiromoto Hisada, Makiko Mizumoto, Yoji Hata, Nobutaka Fujii, Masao Matsuoka, Eiichi Kodama, Shinya Oishi
-
Publication number: 20100330563Abstract: 1-(2-Fluoro-4-thio-?-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity.Type: ApplicationFiled: September 8, 2008Publication date: December 30, 2010Applicant: YAMASA CORPORATIONInventors: Eiichi Kodama, Masao Matsuoka, Noriyuki Ashida
-
Patent number: 7625877Abstract: The present invention provides a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue. The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. The derivative is useful as a medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: November 19, 2007Date of Patent: December 1, 2009Assignee: Yamasa CorporationInventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Publication number: 20090234110Abstract: The present invention provides a method for producing a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: (wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen or a phosphoryl group. The present invention also provides the derivative, and a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. The derivative is useful as a medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).Type: ApplicationFiled: May 20, 2009Publication date: September 17, 2009Inventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Publication number: 20080153774Abstract: The present invention provides a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: (wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue). The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor.Type: ApplicationFiled: November 19, 2007Publication date: June 26, 2008Inventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Patent number: 7339053Abstract: The present invention provides a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: (wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue). The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. Such derivative is useful as medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: March 24, 2005Date of Patent: March 4, 2008Assignee: Yamasa CorporationInventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Publication number: 20050215512Abstract: The present invention provides a 4?-C-substituted-2-haloadenosine derivative represented by the following formula (wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue). The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor.Type: ApplicationFiled: March 24, 2005Publication date: September 29, 2005Inventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Patent number: 6403568Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.Type: GrantFiled: August 30, 2001Date of Patent: June 11, 2002Assignee: Yamasa CorporationInventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya
-
Publication number: 20020022722Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: 1Type: ApplicationFiled: August 30, 2001Publication date: February 21, 2002Inventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya
-
Patent number: 6333315Abstract: The invention provides 4′-C-ethynyl purine nucleosides represented by formula [I]: wherein B represents a base selected from the group consisting of purine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.Type: GrantFiled: May 12, 2000Date of Patent: December 25, 2001Assignee: Yamasa CorporationInventors: Hiroshi Ohrui, Eiichi Kodama, Satoru Kohgo, Hiroaki Mitsuya, Masao Matsuoka, Kenji Kitano
-
Patent number: 6291670Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.Type: GrantFiled: May 12, 2000Date of Patent: September 18, 2001Assignee: Yamasa CorporationInventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya